Phase III Study of ASP2151 in Herpes Simplex Patients

Phase 3CompletedNCT01959295

Maruho Co., Ltd.468 enrolled

Overview

To evaluate the efficacy and safety of ASP2151 in patients with herpes simplex.

A double-blind, randomized, placebo-controlled, parallel-group study will be conducted to evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (labial/facial herpes or recurrent genital herpes). The efficacy will be evaluated for the primary endpoint defined as, "the proportion of subjects achieving lesion healing by Day 8 of study treatment" to demonstrate the superiority of ASP2151 to placebo. The safety will be evaluated based on adverse events, laboratory tests, vital signs, and ECGs.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

468

Conditions

Herpes Simplex

Interventions

ASP2151DRUG

200 mg once daily

ASP2151 placeboDRUG

once daily

Eligibility

Sex: ALLMin age: 20 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients with a rash associated with moderate or severe herpes simplex, for which oral antiviral medication is indicated * Labial/facial herpes: Patients with at least 10 papulae or vesicles/pustules * Recurrent genital herpes: Patients with at least 5 papulae or vesicles/pustules on the genital organs or in the genital and circumanal region 2. Patients who can start receiving the study drug within 48 hours after onset of rash 3. Age: 20 years or older, but younger than 80 years Exclusion Criteria: 1. Patients who are not expected to have an adequate response to oral antiviral medication 2. An extreme decline in immune function 3. Presence of serious complications 4. Patients found to meet any of the following conditions based on laboratory tests performed within 14 days before informed consent: * AST or ALT ≥ 2.5 x upper limit of normal * Platelet count \< lower limit of normal * Serum creatinine ≥ 1.5 mg/dL * Creatinine clearance \< 30 mL/min 5. Current or previous history of malignant tumor within 5 years before informed consent 6. Diagnosis of autoimmune disease 7. Evidence of bone marrow suppression

Locations (3)

Unnamed facility

Sapporo, Hokkaido, Japan

Unnamed facility

Yokohama, Kanagawa, Japan

Unnamed facility

Nakano-ku, Tokyo, Japan

Outcomes

Primary Outcomes

Percentage of Participants With Healing by Day 8

The percentage of participants achieving lesion healing by Day 8 of study treatment

Time frame: 8days

Secondary Outcomes

Time to Healing

The criteria for determining healing are as follows: 1. A condition where all erythematous and papular lesions, vesicular and pustular lesions, and erosive and ulcerative lesions have been resolved, and either the complete resolution of crusts or the complete epithelialization beneath any remaining crusts has been achieved. 2. In participants where no crust has formed, a condition characterized by the epithelialization of erosions/ulcers formation in mucosal lesions and potentially other affected areas. 3. In participants where no vesicles or pustules have formed, a condition characterized by the complete resolution of all erythematous and papular lesions

Time frame: 29days

Time to Complete Crusting

The criteria for complete crust formation are outlined as follows: 1. A condition where all erythematous and papular lesions, vesicular and pustular lesions, and erosive and ulcerative lesions have been resolved, and all rashes are crusted (epithelialization beneath is not required). 2. In participants where no crust has formed, a condition characterized by the epithelialization of erosions/ulcers formation in mucosal lesions and potentially other affected areas. 3. In participants where no vesicles or pustules have formed, a condition characterized by the complete resolution of all erythematous and papular lesions.

Time frame: 29days

Time to Virus Disappearance

The day of viral disappearance is the first day on which the results of viral isolation continuously show 'HSV negative' until the final implementation day. The negative means that the results of the isolation and culture are negative, or the isolation and culture has not been performed due to complete crusting or healing of the lesion site.

Time frame: 29days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.